Pregabalin: a new anxiolytic

Bibliography

• KESSLER RC, MCGONAGLE KA, ZHAO S et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry (1994) 51:8–19.
   PubMed Web of Science ®Google Scholar
• SCHNEIER FR, JOHNSON J, HORNIG CD, LIEBOWITZ MR, WEISSMAN MM: Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch. Gen. Psychiatry (1992) 49:282–288.
   PubMed Web of Science ®Google Scholar
• KESSLER RC, DUPONT RL, BERGLUND P, WITTCHEN HU: Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am. J. Psychiatry (1999) 156:1915–1923.
   PubMed Web of Science ®Google Scholar
• KHAN A, LEVENTHAL RM, KHAN S,BROWN WA: Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database. J. Affect. Disord. (2002) 68:183–190.
   PubMed Web of Science ®Google Scholar
• GELENBERG A: Psychiatric and SomaticMarkers of Anxiety: Identification and Pharmacologic Treatment. Primary Care Companion j Clin. Psychiatry(2000) 2:49–54.
   PubMedGoogle Scholar
• BALLENGER J, DAVIDSON J, LECRUBIER Y, NUTT D: A proposed algorithm for improved recognition and treatment of the depression/anxiety spectrum in primary care. International Consensus Group on Depression and Anxiety. Prim. Care Companion I. Clin. Psychiatry (2001) 3:44–52.
   PubMedGoogle Scholar
• ANDRUSZKIEWICZ RS, SILVERMAN RB: A convenient synthesis of 3-alky1-4-aminobutanoic acids. Synthesis (1989):953–955.
   Web of Science ®Google Scholar
• •Synthesis of PGB.
   Google Scholar
• TAYLOR CP, VARTANIAN MG: Profile of anticonvulsant activity of CI-1008 (Pregabalin) in animal model. Epilepsia (1997) 38\(Suppl. 8):35.
   Google Scholar
• CZUCZWAR SJ, PATSALOS PN: The new generation of GABA enhancers: Potential in the treatment of epilepsy. CNS Drugs (2001) 15(5):339–350.
   PubMed Web of Science ®Google Scholar
• BRYANS JS, WUSTROW DJ: 3-Substituted GABA analogs with central nervous system activity: a review. Med. Res. Rev (1999) 19(2):149–177.
   PubMed Web of Science ®Google Scholar
• •Overview of GBP and PGB potential applications.
   Google Scholar
• DIMOND KR, PANDE AC, LAMOREAUX L, PIERCE MW: Effect of gabapentin (neurotonin) on mood and well-being in patients with epilepsy. Frog. Nemo-Psychopharmacol Biol. Psychiatry (1996) 20:407–417.
   PubMed Web of Science ®Google Scholar
• FINK K, DOOLEY DJ, MEDER WP et al.: Inhibition of neuronal Ca 2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology (2002) 42:229–236.
   PubMed Web of Science ®Google Scholar
• •Suggested mechanism of action of PGB and GBP in in vitro human neocortex studies.
   Google Scholar
• GEE NS, BROWN JP, DISSANAYAKE VUK, OFFORD J, THRULOW R, WOODRUFF GN: The novel anticonvulsant drug, gabapentin (neurontin), binds to the a28 subunit of a calcium channel. ./. Biol. Chem. (1996) 271(10):5768–5776.
   PubMed Web of Science ®Google Scholar
• •Suggested mechanism of action of GBP.
   Google Scholar
• WHITWORTH TL, QUICK MW: Upregulation of 7-aminobutyric acid transporter expression: role of alkylated y-aminobutyric acid derivatives. Biochem. Soc. Trans. (2001) 29(6):736–741.
   PubMedGoogle Scholar
• FIELD MJ, OLES RJ, LEWIS AS, MCCLEARY S, HUGHES J, SINGH I: Gabapentin (neuroptin) and S (+)-3-isolbutylgaba represent a novel class of selective antihyperalgesic agents. Br. .1. Pharmacol (1997) 121:1513–1522.
   Google Scholar
• FIELD MJ, HOLLOMAN EF, MCCLEARY S, HUGHES J, SINGH L: Evaluation of gabapentin and S (+)-3-isobutylgaba in a rat model of postoperative pain. I Pharmacol Exp. Ther. (1997) 282:1242–1246.
   PubMed Web of Science ®Google Scholar
• FIELD MJ, MCCLEARY S, HUGHES J,SINGH L: Gabapentin and pregabalin, but not morphine and amitripyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain (1999) 80:391–398.
   PubMed Web of Science ®Google Scholar
• HOUGHTON AK, JU Y, WESTLUND KN: S (+)-3-isobutylgaba and its stereoisomer reduces the amount of inflammation and hyperalgesia in an acute animal model in the rat. J. Pharmacol Exp. The]: (1998) 285:533–538.
   Google Scholar
• CORRIGAN BW, POOL WE POSVAR EL et al.: Metabolic disposition of pregabalin in healthy volunteers. Gin. Pharmacol Ther. (2001) 69(2):18 (Abstract PI–68).
   Google Scholar
• •Pharmacokinetics of PGB in healthy volunteers.
   Google Scholar
• BOCKBRADER HN, HUNT T, STRAND J et al.: Pregabalin pharmacokinetics and safety in healthy volunteers: results from two Phase I studies. Neurology (2000) 54(7, Suppl. 3) (Abstract 421).
   Google Scholar
• BUSCH JA, STRAND JC, POSVAR ELet al.: Synopsis of two Phase I trials showing the main pharmacokinetics properties of pregabalin. Pregabalin (CI-1008) single-dose pharmacokinetics and safty/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses. Epilepsia (1998) 39\(Suppl. 6):58.
   Google Scholar
• SELAK I: Pregabalin (Pfizer). Carr: Opin. Investig. Drugs (2001) 2(6):828–834.
   PubMedGoogle Scholar
• STEWART BH, KUGLER AR, THOMPSON PR, BOCKBRADER HN: A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm. Res. (1993) 10:276–281.
   PubMed Web of Science ®Google Scholar
• VOLLMER KO, ANHUT H, YHOMANN P, WAGNER F, JAHNCHEN D: Pharmacokinetic model and absolute bioavailability of the new anticonvulsant Gabapentin. Adv. Epileptol (1989) 17:209–211.
   Google Scholar
• PENUCCA E: Global evaluation of Phase III trial, efficacy and safety of pregabalin as add-on treatment in patients with partial seizures. New Anti-Epileptic Drugs - Fifth Eilat Conference, Eilat, Israel. IDdb Meeting Report (2000).
   Google Scholar
• DEVINSKY 0, CRAMER J: Safety and efficacy of new anti-epileptic drugs. Neurol (2000) 55(11):11–16.
   Google Scholar
• LACOBELLIS D, ALLEN R, LAMOUREAUX L, POOL RM: A double-blind, placebo controlled, trial of pregabalin for the treatment of painful diabetic neuropathy. Neurology (2000) 54(7, Suppl. 3):177 (Abstract).
   Google Scholar
• BACKONJA M, BEYDOUN A, EDWARDS KR: Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: a multicenter, double-blind, placebo-controlled trial in patients with epilepsy. J. Am. Med. Assoc. (1998) 280(21):1831–1836.
   PubMed Web of Science ®Google Scholar
• HILL CM, BALKENOHL M, THOMAS DW, WALKER R, MATHE H, MURRAY G: Pregabalin in patients with postoperative dental pain. Ear. I Pain (2001) 5:119–124.
   PubMed Web of Science ®Google Scholar
• ANDREWS N, LOOMIS S, BLAKE R, FERRIGAN L, SINGH L, MCKNIGHT AT: Effect of gabapentin-like compounds on development and maintenance of morphine-induced conditioned place preference. Psychopharmacology (2001) 157:381–387.
   PubMed Web of Science ®Google Scholar
• MANEUF YP, HUGHES J, MCKNIGHT AT: Gabapentin inhibits the substance P-facilitated K+-evoked release of [31-I] glutamate from rat caudal trigeminal nucleus slices. Pain (2001) 93:191–196.
   PubMed Web of Science ®Google Scholar
• FRENCH JA, MALICSI JR, KUGLER AR, KNAPP LE, BOCKBRADER HN, GARAFOLO EA: Pregabalin adjunct therapy in patients with partial seizures. Epilepsia (1999) 40(S7):106.
   Google Scholar
• BEYDOUN A, UTHMAN BM, RAMSAY RE et al.: Pregabalin add-on trial: a double-blind, multi-centre study in patients with partial seizures. Epilepsia (1999) 40(S7):10.
   Google Scholar
• CORBIN A, YOUNG J, LAMOREAUX L: MI Pregabalin reduces pain in patients with postherpetic neuralgioa: Supportive data from SF-Mcgill Pain Questionnaire (SF-MPQ). Pain (2002) 3(2, Suppl. 1)47 (Abstract).
   Google Scholar
• PANDE AC, CROCKATTJC, JANNEY C et al.: Pregabalin treatment of generalized anxiety disorder (GAD) 2000: Three randomized placebo controlled trials. Ear: Psychiatry (2000) 15:244S.
   PubMedGoogle Scholar
• •First trial evaluating the efficacy and safety of PGB as an anxiolytic in GAD.
   Google Scholar
• FELTNER DE, POLLACK MH, DAVIDSON JRT et al.: A placebo-controlled, double-blind study of pregabalin treatment of social phobia: outcome and predictors of response. American Psychiatric Association (2002) (Abstract).
   Google Scholar
• •First trial evaluating the efficacy and safety of PGB as an anxiolytic in social anxiety disorder.
   Google Scholar
• ROSNER H, RUBIN L, KESTENBAUM A: Gabapentin adjunctive therapy in neuropathic pain states. Clin. Pain (1996) 12:56–58.
   Web of Science ®Google Scholar
• ROWBOTHAM M, HARDEN N, STACEY B et al.: Gabapentin for the treatment of post-herpetic neuralgia: a randomized controlled trial. JAMA (1998) 280:1837–1842.
   PubMed Web of Science ®Google Scholar
• ROSENBERG JM, HARRELL C, RISTIC H, WERNER RA, DE ROSAYRO AM: The effect of gabapentin on neuropathic pain. Clin. I Pain (1997) 13:251–255.
   PubMed Web of Science ®Google Scholar
• SIST TC, FILADORA VA II, MINER M,LERNA M: Experience with gabapentin for neuropathic pain in the head and neck: report of ten cases. Reg. Anesth. (1997) 22:473–478.
   PubMedGoogle Scholar
• MELLICK GA, MELLICK LB: Reflex sympathetic dystrophy treated with gabapentin. Arch. Phys. Med. Rehabil (1997) 78:98–105.
   PubMed Web of Science ®Google Scholar
• PANDE AC, DAVIDSON JR, JEFFERSON JW et al.: Treatment of social phobia with gabapentin: a placebo-controlled study. J. Clin. Psychopharmacol (1999) 19:341–348.
   PubMed Web of Science ®Google Scholar
• ADELMAN JU, ADELMAN LC, VON SEGGERN R: Cost-effectiveness of antiepileptic drugs in migraine prophylaxis. Headache (2002) 42(10):978–983.
   PubMed Web of Science ®Google Scholar
• MATHEW NT: Antiepileptic drugs in migraine prevention. Headache (2001) 41\(Suppl. 1):518–524.
   Google Scholar
• SOLARO C, LUNARDI GL, CAPELLO E et al.: An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis. Neurology (1998) 51(2):609–611.
   PubMed Web of Science ®Google Scholar
• MUELLER ME, GRUENTHAL M, OLSON WL, OLSON WH: Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch. Phys. Med. Rehabil (1997) 78:521–524.
   PubMed Web of Science ®Google Scholar
• HOUTCHENS MK, RICHERT JR, SAMI A, ROSE JW: Open label gabapentin treatment for pain in multiple sclerosis. Malt. Scler. (1997) 3:250–253.
   PubMed Web of Science ®Google Scholar
• AVERBUCH-HELLER L, TUSA RJ, FUHRY L et al: A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann. Nemo]. (1997) 41:818–825.
   PubMed Web of Science ®Google Scholar
• ADLER CH: Treatment of restless legs syndrome with gabapentin. Clin. Neuropharmacol (1997) 20:148–151.
   PubMed Web of Science ®Google Scholar
• EVIDENTE VG, ADLER CH, CAVINESS JN, GWINN KA: Effective treatment of orthostatic tremor with gabapentin. Mov. Disord. (1998) 13(5):829–831.
   PubMed Web of Science ®Google Scholar
• MILLER RG, MOORED, YOUNG LA et al.: Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Neurology(1996) 47:1383–1388.
   Google Scholar
• HILL DR, SUAM-CHAUHA N, WOODRUFF GN: Localization of [3H]gabapentin to a novel site in rat brain: autoradiographic studies. Ear: Pharmacol (MM. Pharmacol Section) (1993) 244:303–309.
   Google Scholar
• •Paper looking at the localisation of GBP-binding sites.
   Google Scholar
• TAYLOR CP, VARTANIAN MG, YUEN P-W, BIGGE C, SUMAN-CHAUHAN N, HILL DR: Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to M vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res. (1993) 14:11–15.
   PubMed Web of Science ®Google Scholar
• •Paper looking at the site of action of PGB.
   Google Scholar
• SUMAN-CHAUHAN N, WEBDALE L, HILL DR, WOODRUFF GN: Characterization of [3H]-gabapentin binding to a novel site in the rat brain: homogenate binding studies. Ear: J. Pharmacol (1993) 244:293–301.
   Google Scholar
• FINK K, MEDERW, DOOLEY DJ, GOTHERT M: Inhibition of neuronal Ca2+ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br. J. Pharmacol (2000) 130:900–906.
   PubMed Web of Science ®Google Scholar
• •Suggested mechanism of action of GBP.
   Google Scholar
• MEDER W, DOOLEY DJ: Modulation of K±-induced synaptosomal calcium by gabapentin. Brain Res. (2000) 875:157–159.
   PubMed Web of Science ®Google Scholar
• DOOLEY DJ, MIESKE CA, BOROSKY SA: Inhibition of K (+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. NeuroscL Lett. (2000) 280:107–110.
   PubMed Web of Science ®Google Scholar
• DOOLEY DJ, DONOVAN CM, PUGSLEY TA: Stimulus-dependent modulation of [3I-]-norepinephrine release from rat neocortical slices by gabapentin and pregabalin. Pharmacol Exp. Ther: (2000) 295:1086–1093.
   Google Scholar
• DOOLEY DJ, BARTOSZYK GD, HARTENSTEIN J et al.: Preclinical pharmacology of gabapentin. Golden Jubilee Conference and Northern European Epilepsia Meeting, University of York, York, UK (Abstract 8).
   Google Scholar
• HELMER CA, DOOLEY DJ: Differential effects of gabapentin and pregabalin on stimulation - evoked catecholamine release from rat brain slices. DJSoc. _,Neurosei. Abstr: (1998) 24(1):353.
   Google Scholar
• PUGSLEY TA, WHETZEL SZ: Effects Of pregabalin (S-(+)-3-isobutylgaba, CI-1008 on the 3,4 diaminopyridine (DAP)-induced decrease in catecholamine synthesis in the rat brain. SZ Soc. NeuroscL Abstr: (1999) 25(2):744.11.
   Google Scholar
• NG GY, BERTRAND S, SULLIVAN R et al.: Gamma-aminobutyric acid type B receptors with a specific heterodimer composition and post-synaptic actions in hippocampal neurons are targets of anticonvulsants gabapentin action. MM. Pharmacol (2001) 59:144–152.
   PubMed Web of Science ®Google Scholar
• NOZAKI-TAGUCHI N, CHAPLAN SR, HIGUERA ES, AJAKWE RC, YAKSH TL: Vincristine-induced allodynia in the rat. Pain (2001) 93(1):69–76.
   PubMed Web of Science ®Google Scholar
• CHEN S-R, XU Z, PAN H-L: Stereospecific effect of pregabalin on ectopic afferent discharges and neuropathic pain induced by sciatic nerve ligation in rats. Anesthesiology(2001) 95(6):1473–1479.
   PubMed Web of Science ®Google Scholar
• FIELD MJ, OLES RJ, SINGH L: Pregabalin may represent a novel class of anxiolytics agents with a broad spectrum of activity. Br. J. Pharmacol (2001) 132:1–4.
   PubMed Web of Science ®Google Scholar
• PFIZER, INC.: Pfizer restricts use of pregabalin for some clinical trial patients. (12 February 2001) (Press release).
   Google Scholar
• HINDMARCH I, DAWSON J, STANLEY N: The effects of pregabalin (CI-1008), alprazolam, and placebo on cognitive and psychomotor function, car driving, and aspects of sleep in healthy volunteers. American Psychiatric Association (2002) (Abstract).
   Google Scholar
• •Early safety trials on healthy volunteers compared to benzodiazepines.
   Google Scholar
• HINDMARCH I, DAWSON J, STANLEY N: Evaluation of cognitive and psychomotor profile of pregabalin compared to alprazolam in normal volunteers. American Psychiatric Association (2002) (Abstract).
   Google Scholar
• POLLACK MH, FELTNER DE, RICKELS K et al: A placebo controlled, double blind study of pregabalin in treatment of generalized anxiety disorder. American Psychiatric Association (2002) (Abstract).
   Google Scholar
• RICKELS K, POLLACK MH, LYDIARD RB et al.: Efficacy and safety of pregabalin and alprazolam in generalized anxiety disorder. American Psychiatric Association (2002) (Abstract).
   Google Scholar
• POHL RB, ZIMBROFF DL, HARTFORD J et al.: Pregabalin: efficacy in generalized anxiety disorder using a BID regimen. American Psychiatric Association (2002) (Abstract).
   Google Scholar
• •Efficacy of PGB in a twice-daily dosing.
   Google Scholar
• FELTNER DE, POHL R, ZIMBROFF DL et al.: A placebo-controlled, double-blind study of pregabalin dosed twice daily in the treatment of generalized anxiety disorder. American Psychiatric Association (2002) (Abstract).
   Google Scholar
• KASPER S, BLAGDEN M, SEGHERS S et al.: A placebo-controlled study of pregabalin and venlafaxine treatment of GAD. American Psychiatric Association (2002) (Abstract).
   Google Scholar
• •First comparative trial with PGB versus a serotonininoradrenaline re-uptake inhibitor.
   Google Scholar
• KAVOUSSI R, CROCKATT J, WERTH JL, LIU-DUMAW M, PANDE AC: Pregabalin reduced depressive symptoms in patients with generalized anxiety disorder. American Psychiatric Association (2002) (Abstract).
   Google Scholar
• FAKHOURY TA et al: Long term safety and efficacy of pregabalin. Epilepsia (1999) 40\(Suppl. 7):147 (Abstract).
   Google Scholar
• •First long-term efficacy trial with PGB.
   Google Scholar
• HUPPERTZ H-J, FEUERSTEIN TJ, SCHULZE-BONHAGE A: Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia (2001) 42(6):790–792.
   PubMed Web of Science ®Google Scholar